Home » Newsletters » BioWorld Science

BioWorld Science

July 26, 2017

View Archived Issues

Genocea Biosciences announces topline data from phase IIb study of GEN-003

ALT-803 induces NK- and T-cell activation in SIV-infected macaques

GlaxoSmithKline submits sNDA to the FDA for Arnuity Ellipta in children with asthma

Serum 3-nitrotyrosine is a potential prediagnosis biomarker of postsurgery sepsis

Topline data reported from Novavax's phase II study of RSV F vaccine

Phase III study of Keytruda in HNSCC misses primary endpoint

Frontier Biotechnologies enters agreement with Rockefeller University

Aptevo and Alligator Bioscience to codevelop cancer immunotherapy

Ono Pharmaceutical presents promising in vitro and preclinical data for ONO-5450598

Flex Pharma's FLX-787 wins FDA fast track status for muscle cramps in ALS patients

Investigators in China patent MAPK 1 inhibitors

Asthma compounds identified at Sichuan Haisco Pharmaceutical

Karyopharm Therapeutics presents exportin-1 antagonists

UCB files for U.S. and E.U. approvals for Cimzia in moderate to severe chronic plaque psoriasis

Compounds for cancer discovered at Karyopharm Therapeutics

Axsome Therapeutics reports positive topline results from phase I study of AXS-06

Sernova provides update on regenerative medicine therapy for hemophilia A

FDA grants fast track designation to caplacizumab for acquired thrombotic thrombocytopenic purpura

Onconova Therapeutics enters agreements to advance rigosertib in pediatric RASopathies

Tetraphase reports topline results from IGNITE4 trial of eravacycline in cIAI

AntriaBio doses first patient in phase I study of AB-101

Santen initiates phase IIa study of DE-122 for wet AMD

The Medicines Co. provides update on TANGO-2 study of meropenem/vaborbactam

Phase III data for glecaprevir/pibrentasvir combination in HIV-1/HCV coinfected patients presented

Eisai seeks approval of lenvatinib for HCC in U.S. and E.U.

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...